- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02815969
The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
Exploring the Metabolic Profile of Neuroendocrine Tumors
Study Overview
Detailed Description
Rationale:
Neuro-endocrine neoplasms are a diverse group of tumors which encompasses heterogeneous clinical courses. Different NETs are characterized by differences in the synthesis, storage and release of biogenic amines and their metabolites, e.g. indoles, catecholamines and their metabolites. Clinical course, prognosis, and treatment are based, among others, on the origin of the primary tumor. Up to now it was only possible to measure metabolic output of NETs by serotonin in platelets and 5-HIAA in urine. Due to technical improvements we can now measure the complete metabolic pathway of serotonin in plasma and urine, which comprises tryptophan, 5-hydroxytryptophan, serotonin and 5-HIAA, the indol profile. Furthermore, levels of catecholamines and metabolites can now be analyzed in the same sample. This metabolic profiling could potentially lead to improved diagnosis and characterization of NET patients and possibly contribute to subsequent treatment consequences.
Therefore, we want to perform an exploratory study to measure the indol profile, catecholamines and metabolites in patients with NETs of different origin (foregut, midgut and hindgut) and assess differentiation of their metabolic profile.
Objective:
The aim of this study is to explore the added value of the indol profile in comparison to serotonin in platelets and 5-HIAA in urine for diagnosis and potentially management of neuroendocrine tumors including gastrinomas, pNETs and brochopulmonary NETs.
Design:
This is an observational and exploratory study. Participants will be asked for a blood collection and a 24- hour collection of urine. The indol profile and levels of catecholamine and metabolites in PRP, as well as in 24- hour collection of urine will be measured with LC-MS/MS and analyzed.
Study population:
In this study we will use PRP and a 24- hour collection of urine of 70 patients with a foregut NET, 70 patients with a midgut and/or hindgut NET and 70 matched healthy volunteers. Healthy volunteers are matched according to age and sex with the included patients. Matched controls already available in our data bank will be used from the earlier approved SERT study (NCT 01398306)
Main study parameters:
In this exploratory study we will measure the indol profile in patients with a foregut NET, mid- and hindgut NET, and healthy volunteers at the time of diagnosis and during follow up and treatment in plasma and urine.
In addition, levels of catecholamines and metabolites in these three groups will be determined.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Patients with midgut NET already have blood collections and urinary collection as part of evaluation of their treatment. Only for patients with foregut NETs and some of the healthy volunteers one extra blood collection with a vena puncture will be taken. This gives a small risk of bruising. Furthermore a 24-hours collection of urine will be collected with a prescription to their diet 48 hours before the collection. This could give some distress.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Groningen, Netherlands, 9713 GZ
- University Medical Center Groningen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria for all subjects:
- written informed consent
- age above 18 years
Inclusion criteria for patients with a NET: (one of these)
- histologically proven NET, with or without treatment for the NET
- a diagnosis made by a dedicated NET specialist based on a combination of physical symptoms and signs, imaging and laboratory values.
Inclusion criteria for healthy subjects:
- Matching in age (plus or minus 3 years) and sex with one of the included NET patients.
Data of healthy subjects could also be used from the SERT-study, if the subject meets the criteria mentioned above.
Exclusion criteria for all subjects:
- Use of drugs or food supplements that interact with the serotonin-metabolism; all serotonin re-uptake inhibitors, psychotrophic drugs, (other antidepressants; tricyclic antidepressants, MAO-inhibitors, mirtazapin, bupropion, venlafaxin, duloxetin, anxiolytic, antipsychotic and anticonvulsive drugs).
- Drug abuse in the last 8 weeks.
- Use of ≥ 14 alcoholic consumptions a week for women.
- Use of ≥ 21 alcoholic consumptions a week for men.
Exclusion criteria for healthy subjects:
- Having a neuroendocrine tumor or neuroendocrine carcinoma from any grade and location in present or in history.
- Having a malignancy.
- Having an auto-immune disease.
- Having an infection.
- Having renal impairment.
- Use of interferon.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Healthy volunteers
If no material of healthy volunteers of the SERT study can be used, then other matched volunteers are asked for a vena punction and urine collection
|
vena punction and urine collection
|
Patients
Patients are asked for a vena punction and urine collection, if not already done because of medical care.
|
vena punction and urine collection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
indol profile; 5-HTP, Serotonin, 5-Hydroxyindolacetic acid, Tryptophan in platelet rich plasma
Time Frame: at one visit
|
indol profile in platelet rich plasma
|
at one visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
catecholamines; L-DOPA, Dopamine, Norepinephrine, Epinephrine, -Methoxytyramine, Normetanephrine, Metanephrine in platelet rich plasma
Time Frame: at one visit
|
catecholamines in platelet rich plasma
|
at one visit
|
indoles and catecholamines; L-DOPA, 5-HTP, Dopamine, Norepinephrine, Epinephrine, 3-Methoxytyramine, Normetanephrine, Metanephrine, Serotonin, 5-Hydroxyindolacetic acid
Time Frame: at one visit
|
indoles and catecholamines in urine
|
at one visit
|
Collaborators and Investigators
Investigators
- Principal Investigator: A. M.E. Walenkamp, MD, PhD, University Medical Center Groningen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201600496
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Tumors
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Gastroenteropancreatic Neuroendocrine TumorChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced Gastroenteropancreatic Neuroendocrine Tumor
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingNeuroendocrine Tumors,GastroenteropancreaticTaiwan
-
Grupo Espanol de Tumores NeuroendocrinosActive, not recruitingNeuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine TumorSpain
-
Australasian Gastro-Intestinal Trials GroupCompletedMidgut Neuroendocrine Tumours | Pancreatic Neuroendocrine TumoursAustralia
-
Amr Mohamed MDNovatek PharmaceuticalsRecruitingNeuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine NeoplasmUnited States
-
Francesco De CobelliCompleted
-
TaiRx, Inc.Active, not recruitingNeuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine NeoplasmTaiwan
-
Memorial Sloan Kettering Cancer CenterRecruitingNeuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine TumorsUnited States
-
University Hospital, Basel, SwitzerlandSwiss National Science Foundation; Paul Scherrer Institute (PSI)RecruitingNeuroendocrine Neoplasia's (NENs) | Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)Switzerland
Clinical Trials on vena punction
-
University Medical Center GroningenDutch Cancer SocietyRecruiting
-
University Medical Center GroningenThe Netherlands Cancer InstituteActive, not recruitingTesticular CancerNetherlands
-
Recepta BiopharmaCompleted
-
Erasmus Medical CenterNationaal Epilepsie FondsCompletedEpilepsy | Auto-immune EncephalitisNetherlands
-
University Medical Center GroningenCompletedCarcinoma, Renal Cell | Carcinoma | Neuroendocrine Tumors | Carcinoid Tumor | Pancreatic Islet Cell TumorsNetherlands
-
Instituto do Cancer do Estado de São PauloBoston Scientific CorporationRecruitingPancreatic NeoplasmsBrazil
-
University Hospital, ToulouseCompleted
-
Centre Hospitalier Intercommunal CreteilActive, not recruiting
-
University Hospital, Strasbourg, FranceRecruitingAlzheimer Disease | Multiple System Atrophy | Frontotemporal Dementia | Dementia With Lewy Bodies | Parkinson's Disease DementiaFrance
-
University Hospital, ToulouseCompletedPlatelet DysfunctionFrance